Drug intelligence / Profile preview

demexiptiline

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

Demexiptiline is a tricyclic antidepressant (TCA) primarily used in the treatment of depression. It acts by inhibiting the reuptake of norepinephrine and serotonin at nerve terminals, thereby increasing their levels in the brain and contributing to its antidepressant effects. Like other TCAs, it may also have anticholinergic and sedative properties. Demexiptiline was developed and marketed mainly in France under brand names such as Deparon and Tinoran for depressive disorders.

Brand names: DeparonTinoran
Other names: demexiptylineDemexyptiline

Targets

NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on demexiptiline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on demexiptiline.

Explore the full profile